Gadoteric acid: Difference between revisions
No edit summary |
No edit summary |
||
Line 47: | Line 47: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Gadoteric acid''' (trade names '''Artirem''', '''Dotarem''') is a [[macrocycle]]-structured [[gadolinium-based MRI contrast agent]]. It consists of the organic acid [[DOTA (chelator)|DOTA]] as a [[chelating agent]], and [[gadolinium]] (Gd<sup>3+</sup>), and is used in form of the [[meglumine]] salt. | '''Gadoteric acid''' (trade names '''Artirem''', '''Dotarem''') is a [[macrocycle]]-structured [[gadolinium-based MRI contrast agent]]. It consists of the organic acid [[DOTA (chelator)|DOTA]] as a [[chelating agent]], and [[gadolinium]] (Gd<sup>3+</sup>), and is used in form of the [[meglumine]] salt. The drug is approved and used in a number of countries worldwide. It is used to assist imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing [[intracranial]] [[lesion]]s with abnormal [[blood vessel|vascularity]] or abnormalities in the [[blood–brain barrier]]. Its [[paramagnetic]] property reduces the [[Spin-lattice relaxation time|T1]] [[Relaxation (NMR)|relaxation time]] (and to some extent the T2 and T2* relaxation times) in [[NMR]], which is the source of its clinical utility. | ||
==References== | ==References== |
Revision as of 20:21, 10 April 2015
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C16H25GdN4O8 |
Molar mass | 558.64 g/mol |
|
WikiDoc Resources for Gadoteric acid |
Articles |
---|
Most recent articles on Gadoteric acid Most cited articles on Gadoteric acid |
Media |
Powerpoint slides on Gadoteric acid |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Gadoteric acid at Clinical Trials.gov Trial results on Gadoteric acid Clinical Trials on Gadoteric acid at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Gadoteric acid NICE Guidance on Gadoteric acid
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Gadoteric acid Discussion groups on Gadoteric acid Patient Handouts on Gadoteric acid Directions to Hospitals Treating Gadoteric acid Risk calculators and risk factors for Gadoteric acid
|
Healthcare Provider Resources |
Causes & Risk Factors for Gadoteric acid |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Gadoteric acid (trade names Artirem, Dotarem) is a macrocycle-structured gadolinium-based MRI contrast agent. It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt. The drug is approved and used in a number of countries worldwide. It is used to assist imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing intracranial lesions with abnormal vascularity or abnormalities in the blood–brain barrier. Its paramagnetic property reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in NMR, which is the source of its clinical utility.
References
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drug